Abstract: Poster Presentations |

Sitaxsentan Sodium for the Treatment of Pulmonary Hypertension (PAH) in Patients Failing Bosentan: Preliminary Single Center Data FREE TO VIEW

Adaani E. Frost, MD*; Helena Purl, RN
Author and Funding Information

Baylor College of Medicine & The Methodist Hospital, Houston, TX


Chest. 2004;126(4_MeetingAbstracts):885S. doi:10.1378/chest.126.4_MeetingAbstracts.885S-a
Text Size: A A A
Published online


PURPOSE:  Bosentan (BOS) is an oral endothelin A&B receptor antagonist effective for PAH treatment. Patients (Pts.) with initial benefit can deteriorate or develop liver function test abnormalities (LFab) requiring drug cessation. Sitaxsentan (SITAX) is a selective oral endothelin A receptor antagonist in clinical trials. Between 10/01/03 and 1/23/04 13 pts. enrolled at this center in an open-label safety study of SITAX. 11 pts. were previously treated with BOS which was discontinued due to LFab (3) or deteriorating functional capacity and walk test (6MW)(8). We present their short term response to SITAX.

METHODS:  Pts with LFab on BOS (L1-L3)remained off BOS prior to SITAX intiation until LFab normalized. In pts. transitioned due to clinical deterioration (1-7), baseline values were on BOS. 10 pts. have been followed for 12 weeks with 6MW, exam and WHO. The change in 6MW was compared to baseline values using two-sided paired t-test.

RESULTS:  The mean improvement (± SE) in 6MW with SITAX was 36.5 ± 10.56m (p=0.0072). No Pts. with LFab on BOS experienced signficant LFab with SITAX. One pt. (not included due to no efficacy measurements)who refused epoprostenol for clinical deterioration transitioned to SITAX from BOS. This pt. worsened at wk 5 started epoprostenol and subsequently died.

CONCLUSION:  SITAX appears to offer potential as oral therapy for pts. with PAH who fail BOS due to LFab or clinical deterioration.

CLINICAL IMPLICATIONS:  Failure or complications with one endothelin receptor antagonist does not presuppose failure with another. Different endothelin receptor antagonists may offer unique advantages. Pt.BaselineBaseline12 wk12 wkChangeWHO6MWTWHO6MWT6MWTL133592408+49L232753372+97L325792600+21133903432+422329432940324702477+7433303390+60523202342+22634663461−6733873459+72

DISCLOSURE:  A.E. Frost, Encysive,Actelion

Wednesday, October 27, 2004

12:30 PM- 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543